in combination with pembrolizumab
Showing 1 - 25 of >10,000
Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,
Not yet recruiting
- Cervical Cancer
- +2 more
- PRGN-2009 plus Pembrolizumab
- Pembrolizumab alone
-
Bethesda, MarylandNational Institute of Health
Nov 27, 2023
Gastric Cancer, GastroEsophageal Cancer Trial in Aurora, Colorado Springs, Highlands Ranch (Pembrolizumab, Olaparib,
Recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Pembrolizumab
- +2 more
-
Aurora, Colorado
- +2 more
Jan 4, 2023
MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)
Not yet recruiting
- MSI-H Colorectal Cancer
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Aug 17, 2023
GastroEsophageal Cancer, Gastric Cancer Trial in Tampa (Neratinib, Trastuzumab, Oxaliplatin)
Recruiting
- GastroEsophageal Cancer
- Gastric Cancer
- Neratinib
- +4 more
-
Tampa, FloridaMoffitt Cancer Center
Oct 25, 2023
Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)
Not yet recruiting
- Renal Pelvis and Ureter Urothelial Carcinoma
- Biopsy
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023
Urothelial Carcinoma Trial in New York (Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab)
Not yet recruiting
- Urothelial Carcinoma
- Naptumomab Estafenatox
- +2 more
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
May 30, 2023
Solid Tumors Trial in Charlottesville (XmAb662, Keytruda® (pembrolizumab))
Recruiting
- Solid Tumors
- XmAb662
- Keytruda® (pembrolizumab)
-
Charlottesville, VirginiaUniversity Of Virginia Comprehensive Cancer Center
Aug 10, 2023
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
Gastric Cancer Stage IIIB-IIIC Trial in Shanghai (Pembrolizumab + SOX)
Recruiting
- Gastric Cancer Stage IIIB-IIIC
- Pembrolizumab + SOX
-
Shanghai, Shanghai, ChinaRuijin Hospital
Sep 7, 2023
Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Zanzalintinib
- +2 more
- (no location specified)
Oct 9, 2023
Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer Trial (Pembrolizumab, Lenvatinib)
Not yet recruiting
- Recurrent Vulvar Cancer
- +3 more
- (no location specified)
Jun 12, 2023
Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue Trial in Warsaw (Pembrolizumab, Eftilagimod alpha)
Recruiting
- Neoadjuvant
- +3 more
- Pembrolizumab, Eftilagimod alpha
-
Warsaw, PolandMaria Sklodowska-Curie National Research Institute of Oncology
Nov 7, 2023
Advanced Solid Tumor, Metastatic Solid Tumor Trial in Nashville, Dallas, Fairfax (JZP898, Pembrolizumab)
Not yet recruiting
- Advanced Solid Tumor
- Metastatic Solid Tumor
-
Nashville, Tennessee
- +2 more
Oct 26, 2023
Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)
Not yet recruiting
- Hodgkin Lymphoma
- Brentuximab vedotin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 20, 2023
Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
NSCLC (NSCLC) Trial (Sotorasib, Pembrolizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- (no location specified)
Jun 26, 2023
Lung Cancer Trial (TILT-123, Pembrolizumab)
Not yet recruiting
- Lung Cancer
- TILT-123
- Pembrolizumab
- (no location specified)
Nov 5, 2023
Metastatic Melanoma, Unresectable Melanoma, Melanoma Trial (Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover
Not yet recruiting
- Metastatic Melanoma
- +2 more
- Lifileucel plus Pembrolizumab
- Pembrolizumab with Optional Crossover Period
- (no location specified)
Feb 13, 2023
Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma Trial (XNW5004, Pembrolizumab 25 mg/mL Solution for
Not yet recruiting
- Carcinoma
- +7 more
- XNW5004
- Pembrolizumab 25 mg/mL Solution for Injection
- (no location specified)
Aug 31, 2023
Solid Tumor Trial in San Antonio, Tyler, Spokane (TU2218 + Pembrolizumab)
Recruiting
- Solid Tumor
- TU2218 + Pembrolizumab
-
San Antonio, Texas
- +2 more
Mar 26, 2023